Eli Lilly’s growth drivers, Verzenio and Jardiance, suffer clinical setbacks

Besides the diabetes and obesity duo of Mounjaro and Zepbound, the SGLT2 inhibitor Jardiance and the CDK4/6 cancer drug Verzenio were cited as the main growth drivers for Eli Lilly’s first quarter. But both meds had some bad news to report from late-stage clinical trials.